Lithium
Lithobid, Lithonate (lithium) is a small molecule pharmaceutical. Lithium was first approved as Lithobid on 1982-01-01. It is used to treat bipolar disorder, conduct disorder, depressive disorder, and post-traumatic stress disorders in the USA. The pharmaceutical is active against inositol monophosphatase 1. In addition, it is known to target glycogen synthase kinase-3 beta.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Lithobid (generic drugs available since 1986-05-21, discontinued: Eskalith, Lithane, Lithonate, Lithotabs)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lithium carbonate
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lithobid | New Drug Application | 2020-02-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bipolar disorder | EFO_0000289 | D001714 | F30.9 |
| conduct disorder | EFO_0004216 | D019955 | F91 |
| depressive disorder | EFO_1002014 | D003866 | F32.A |
| post-traumatic stress disorders | EFO_0001358 | D013313 | F43.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX04: Lithium succinate
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AN: Lithium antipsychotics
— N05AN01: Lithium
HCPCS
Code | Description |
|---|---|
| A4235 | Replacement battery, lithium, for use with medically necessary home blood glucose monitor owned by patient, each |
| A4601 | Lithium ion battery, rechargeable, for non-prosthetic use, replacement |
| A4602 | Replacement battery for external infusion pump owned by patient, lithium, 1.5 volt, each |
| E2397 | Power wheelchair accessory, lithium-based battery, each |
| K0604 | Replacement battery for external infusion pump owned by patient, lithium, 3.6 volt, each |
| K0605 | Replacement battery for external infusion pump owned by patient, lithium, 4.5 volt, each |
| L7367 | Lithium ion battery, rechargeable, replacement |
| L7368 | Lithium ion battery charger, replacement only |
| L8623 | Lithium ion battery for use with cochlear implant device speech processor, other than ear level, replacement, each |
| L8624 | Lithium ion battery for use with cochlear implant or auditory osseointegrated device speech processor, ear level, replacement, each |
Show 2 more
Clinical
Clinical Trials
98 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypothyroidism | D007037 | EFO_0004705 | E03.9 | — | 4 | 1 | 2 | 3 | 9 |
| Cataract | D002386 | EFO_0001059 | H26.9 | — | — | — | 2 | 3 | 5 |
| Depression | D003863 | F33.9 | — | — | 1 | 2 | 1 | 4 | |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | — | — | 1 | — | 1 |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | — | — | 1 | — | 1 |
| Papillary thyroid cancer | D000077273 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 1 | 1 | 2 | — | — | 4 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | — | 2 | — | — | 3 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | 2 | — | — | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 1 | — | — | 1 |
| Postoperative cognitive complications | D000079690 | — | — | 1 | — | — | 1 | ||
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 1 | — | — | 1 |
| Autoimmune hypothyroidism | C562768 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 8 | 1 | — | — | — | 8 | ||
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 2 | — | — | 3 | 5 | |
| Euthyroid sick syndromes | D005067 | EFO_1000931 | E07.81 | — | 2 | — | — | 2 | 4 |
| Heart failure | D006333 | EFO_0003144 | I50 | 3 | 3 | — | — | 1 | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 2 | 3 |
| Covid-19 | D000086382 | U07.1 | — | 2 | — | — | 1 | 3 | |
| Glioblastoma | D005909 | EFO_0000515 | 1 | 1 | — | — | — | 2 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 2 | — | — | — | 2 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | 2 | — | — | — | 2 |
| Neoplasms | D009369 | C80 | 1 | 1 | — | — | 1 | 2 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | 1 | — | — | — | 1 | 2 | ||
| Analgesia | D000698 | 1 | — | — | — | — | 1 | ||
| Anesthesia | D000758 | 1 | — | — | — | — | 1 | ||
| Local anesthesia | D000772 | 1 | — | — | — | — | 1 | ||
| Helminthiasis | D006373 | EFO_1001342 | B65-B83 | 1 | — | — | — | — | 1 |
| Allergic rhinitis | D065631 | J30.9 | 1 | — | — | — | — | 1 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | — | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | 1 | — | — | — | — | 1 | |
| Chronic progressive multiple sclerosis | D020528 | 1 | — | — | — | — | 1 | ||
| Prostatic neoplasms | D011471 | C61 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Edentulous jaw | D007575 | — | — | — | — | 3 | 3 | ||
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 2 | 2 |
| Astigmatism | D001251 | H52.2 | — | — | — | — | 2 | 2 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Alveolar bone loss | D016301 | — | — | — | — | 1 | 1 | ||
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 1 | 1 |
| Coronary disease | D003327 | — | — | — | — | 1 | 1 | ||
| Tooth diseases | D014076 | — | — | — | — | 1 | 1 | ||
| Refractive errors | D012030 | EFO_0003908 | H52.7 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LITHIUM |
| INN | — |
| Description | Lithium Citrate, Lithonate (lithium) is a small molecule pharmaceutical. Lithium was first approved as Lithium Citrate on 1982-01-01. It is used to treat in the USA. The pharmaceutical is active against inositol monophosphatase 1. In addition, it is known to target glycogen synthase kinase-3 beta. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | [LiH] |
Identifiers
| PDB | — |
| CAS-ID | 7439-93-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2146126 |
| ChEBI ID | 30146 |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
IMPA1
IMPA1
Organism
Homo sapiens
Gene name
IMPA1
Gene synonyms
IMPA
NCBI Gene ID
Protein name
inositol monophosphatase 1
Protein synonyms
D-galactose 1-phosphate phosphatase, IMP 1, IMPase 1, inositol(myo)-1(or 4)-monophosphatase 1, Inositol-1(or 4)-monophosphatase 1, Lithium-sensitive myo-inositol monophosphatase A1, myo-inositol monophosphatase 1, testicular tissue protein Li 94
Uniprot ID
Mouse ortholog
Impa1 (55980)
inositol monophosphatase 1 (O55023)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 130,833 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lithobid
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,025 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more